581 related articles for article (PubMed ID: 8469318)
1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Neurology; 1993 Apr; 43(4):655-61. PubMed ID: 8469318
[TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study.
Chisari CG; Aguglia U; Amato MP; Bergamaschi R; Bertolotto A; Bonavita S; Morra VB; Cavalla P; Cocco E; Conte A; Cottone S; De Luca G; Di Sapio A; Filippi M; Gallo A; Gasperini C; Granella F; Lus G; Maimone D; Maniscalco GT; Marfia G; Moiola L; Paolicelli D; Pesci I; Ragonese P; Rovaris M; Salemi G; Solaro C; Totaro R; Trojano M; Vianello M; Zaffaroni M; Lepore V; Patti F;
Neurotherapeutics; 2024 May; ():e00363. PubMed ID: 38714462
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
Kappos L; Edan G; Freedman MS; Hartung HP; Montalbán X; Barkhof F; Koelbach R; MacManus DG; Wicklein EM;
J Neurol; 2024 May; ():. PubMed ID: 38730097
[TBL] [Abstract][Full Text] [Related]
4. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
[TBL] [Abstract][Full Text] [Related]
5. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Paty DW; Li DK
Neurology; 1993 Apr; 43(4):662-7. PubMed ID: 8469319
[TBL] [Abstract][Full Text] [Related]
6. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
[TBL] [Abstract][Full Text] [Related]
7. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
[TBL] [Abstract][Full Text] [Related]
8. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
Lublin FD; Reingold SC
Neurology; 1996 Apr; 46(4):907-11. PubMed ID: 8780061
[TBL] [Abstract][Full Text] [Related]
9. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
[TBL] [Abstract][Full Text] [Related]
10. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH
Mult Scler; 1995 Jun; 1(2):118-35. PubMed ID: 9345462
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
Simon JH; Jacobs LD; Campion M; Wende K; Simonian N; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Alam JJ; Fischer JS; Goodkin DE; Granger CV; Lajaunie M; Martens-Davidson AL; Meyer M; Sheeder J; Choi K; Scherzinger AL; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Whitham RH
Ann Neurol; 1998 Jan; 43(1):79-87. PubMed ID: 9450771
[TBL] [Abstract][Full Text] [Related]
12. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.
Millefiorini E; Gasperini C; Pozzilli C; D'Andrea F; Bastianello S; Trojano M; Morino S; Morra VB; Bozzao A; Calo' A; Bernini ML; Gambi D; Prencipe M
J Neurol; 1997 Mar; 244(3):153-9. PubMed ID: 9050955
[TBL] [Abstract][Full Text] [Related]
13. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Rudick RA; Goodkin DE; Jacobs LD; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Granger CV; Simon JH; Alam JJ; Simonian NA; Campion MK; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Whitham RH
Neurology; 1997 Aug; 49(2):358-63. PubMed ID: 9270562
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Edan G; Miller D; Clanet M; Confavreux C; Lyon-Caen O; Lubetzki C; Brochet B; Berry I; Rolland Y; Froment JC; Cabanis E; Iba-Zizen MT; Gandon JM; Lai HM; Moseley I; Sabouraud O
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):112-8. PubMed ID: 9048709
[TBL] [Abstract][Full Text] [Related]
15. A cost-utility analysis of interferon beta for multiple sclerosis.
Parkin D; McNamee P; Jacoby A; Miller P; Thomas S; Bates D
Health Technol Assess; 1998; 2(4):iii-54. PubMed ID: 9580870
[No Abstract] [Full Text] [Related]
16. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
Rudick RA; Simonian NA; Alam JA; Campion M; Scaramucci JO; Jones W; Coats ME; Goodkin DE; Weinstock-Guttman B; Herndon RM; Mass MK; Richert JR; Salazar AM; Munschauer FE; Cookfair DL; Simon JH; Jacobs LD
Neurology; 1998 May; 50(5):1266-72. PubMed ID: 9595973
[TBL] [Abstract][Full Text] [Related]
17. Early treatment trials with interferon beta in multiple sclerosis.
Panitch HS
Mult Scler; 1995; 1 Suppl 1():S17-21. PubMed ID: 9345392
[TBL] [Abstract][Full Text] [Related]
18. The historical development of interferons as multiple sclerosis therapies.
Johnson KP
J Mol Med (Berl); 1997 Feb; 75(2):89-94. PubMed ID: 9083926
[TBL] [Abstract][Full Text] [Related]
19. Interferon beta therapy for multiple sclerosis.
Goodkin DE
Lancet; 1998 Nov; 352(9139):1486-7. PubMed ID: 9820292
[No Abstract] [Full Text] [Related]
20. Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis.
Munschauer FE; Stuart WH
Clin Ther; 1997; 19(5):868-82. PubMed ID: 9385476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
